Shareholders who purchased shares of REPL during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares of REPL during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be ...

Core Viewpoint - Rosen Law Firm has filed a class action lawsuit on behalf of investors who purchased Replimune Group, Inc. securities during the specified Class Period, alleging that the company made materially false and misleading statements regarding its business and operations [1][5]. Group 1: Lawsuit Details - The class action lawsuit pertains to securities purchased between November 22, 2024, and July 21, 2025 [1]. - The lawsuit claims that defendants overstated the prospects of the IGNYTE trial, which the FDA deemed inadequate, leading to misleading statements about Replimune's business and operations [5]. - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. Group 2: Next Steps for Investors - Investors wishing to join the class action can do so by visiting the provided link or contacting the law firm directly [3][6]. - A lead plaintiff must file a motion with the court by September 22, 2025, to represent other class members [3]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest against a Chinese company at the time [4]. - The firm has been consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions for investors [4].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Replimune Group, Inc. due to significant stock losses following a negative FDA response regarding its drug application [3][5][6]. Group 1: Legal Investigation and Claims - The law firm is encouraging investors who suffered losses exceeding $50,000 in Replimune between November 22, 2024, and July 21, 2025, to discuss their legal options [1]. - A federal securities class action has been filed against Replimune, with a deadline of September 22, 2025, for investors to seek the role of lead plaintiff [3][8]. - The complaint alleges that Replimune and its executives made false or misleading statements regarding the IGNYTE trial, which the FDA deemed inadequate [5]. Group 2: Impact of FDA Response - On July 22, 2025, Replimune received a Complete Response Letter from the FDA, indicating that the application for RP1 was not approvable in its current form due to inadequacies in the IGNYTE trial [6]. - Following the FDA's announcement, Replimune's stock price fell over 73% during intraday trading on the same day [7]. Group 3: Company Background - Faruqi & Faruqi, LLP is a national securities law firm with a history of recovering hundreds of millions of dollars for investors since its establishment in 1995 [4].

Core Viewpoint - A class action securities lawsuit has been filed against Replimune Group, Inc. due to alleged securities fraud affecting investors between November 22, 2024, and July 21, 2025 [1][2] Group 1: Lawsuit Details - The complaint alleges that defendants made false statements regarding the IGNYTE trial, overstating its prospects despite known material issues, leading to the FDA deeming the trial inadequate [2] - Defendants' statements about Replimune's business and operations were claimed to be materially false and misleading, lacking a reasonable basis at all relevant times [2] Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until September 22, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require serving as lead plaintiff [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees [3] Group 3: Firm Background - Levi & Korsinsky has a 20-year history of securing hundreds of millions for shareholders and is recognized as one of the top securities litigation firms in the U.S. [4]

Core Viewpoint - A class action securities lawsuit has been filed against Replimune Group, Inc. for alleged securities fraud affecting investors between November 22, 2024, and July 21, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that defendants made false statements regarding the IGNYTE trial's prospects, which were known to be inadequate by the defendants, leading to misleading statements about Replimune's business and operations [2]. - The complaint highlights that the FDA deemed the IGNYTE trial inadequate and not well-controlled, which contradicts the defendants' public statements [2]. Group 2: Investor Information - Investors who suffered losses during the specified period have until September 22, 2025, to request to be appointed as lead plaintiff, although participation in any recovery does not require this [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, ensuring no financial obligation to participate [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years [4]. - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the United States [4].

NEW YORK, July 31, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Replimune Group, Inc. (NASDAQ: REPL). Shareholders who purchased shares of REPL during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/replimune-group-inc-loss-submission-form-3/?id=158801&from=4 DEADLINE: September ...

Group 1 - China Biopharmaceutical (1177.HK) saw a rise of over 3% after announcing a successful licensing agreement with Merck for its PD-1/VEGF dual antibody, expecting a $300 million milestone payment soon [1] - CSPC Pharmaceutical Group (1093.HK) increased by over 5% following the announcement of an exclusive licensing agreement with Madrigal Pharmaceuticals for the global development of its GLP-1 receptor agonist SYH2086 [1] - Youzan (8083.HK) surged over 7% as it projected a revenue of approximately 709 to 719 million RMB for the first half of the year, a year-on-year increase of about 3.3% to 4.8%, and a net profit of 68 to 74 million RMB, marking a turnaround from a loss last year [1] Group 2 - Xingsheng International (6058.HK) rose nearly 18% after the bank announced its commitment to embrace technological transformation and explore stablecoins and AI initiatives [2] - New Oriental Education (9901.HK) fell nearly 4% after reporting a 9.4% year-on-year increase in net revenue to $1.243 billion for the fourth quarter of fiscal year 2025, but a 73.7% drop in net profit [2] - Kingdee International (0268.HK) saw a rise of over 7% as it announced a board meeting to review its interim results and potential dividend distribution [2] Group 3 - Macau gaming stocks rose, with MGM China (2282.HK) up over 4% after Macquarie raised its forecast for Macau's total gaming revenue for 2025 by 5% to 235.7 billion RMB, indicating a year-on-year growth of 4% [3] - Gold stocks in Hong Kong continued to decline, with Tongguan Gold (0340.HK) dropping over 9% for six consecutive days, as spot gold prices fell below $3,270 per ounce [4] - Kangfang Biopharma (9926.HK) rose nearly 5% after announcing the completion of the first patient dosing in a pivotal clinical trial for its PD-1/VEGF dual-specific antibody [4] Group 4 - Weishi Jiajie (0856.HK) increased by over 3% as a report indicated that its Southeast Asia business is expected to see a significant revenue increase of 74% in 2024, with net profit contributing about 51% [5] Group 5 - Meta (META.US) exceeded revenue expectations and provided strong guidance for the current quarter, leading to an after-hours increase of over 11% [6] - Microsoft (MSFT.US) reported an 18% year-on-year growth in revenue, driven by its cloud business, with Azure revenue up 34% for the full year, resulting in an after-hours increase of over 8% [6] - Wingstop (WING.US) surged by 26.85% after reporting adjusted earnings per share of $1.00 for the second quarter, exceeding analyst expectations [6] Group 6 - Several biopharmaceutical stocks surged, with Replimune (REPL.US) up 101.33% following news of regulatory changes at the FDA that may ease pressure on gene therapy and vaccine companies [7] - Marvell Technology (MRVL.US) rose 7.07% after announcing a partnership with Rebellions to provide AI systems for regional projects in Asia-Pacific and the Middle East [7] - Palo Alto Networks (PANW.US) fell 5.58% after agreeing to acquire CyberArk Software for approximately $25 billion [8]

周三，部分生物制药公司股价飙升，截至发稿，Replimune(REPL.US)飙升逾85%， Sarepta Therapeutics (SRPT.US)上涨超16%， Capricor Therapeutics(CAPR.US)大涨超18%。消息面上，美国FDA生物制品评 估与研究中心主任普拉萨德在上任不到三个月后离职，正值FDA对多款基因疗法和疫苗采取严格监管措 施，引发市场关注。分析人士指出，他的离任可能有助于缓解监管压力，被视为基因疗法和疫苗企业的 利好消息。 ...

智通财经APP获悉，周三，部分生物制药公司股价飙升，截至发稿，Replimune(REPL.US)飙升逾85%， Sarepta Therapeutics (SRPT.US)上涨超16%，Capricor Therapeutics(CAPR.US)大涨超18%。消息面上，美 国FDA生物制品评估与研究中心主任普拉萨德在上任不到三个月后离职，正值FDA对多款基因疗法和疫 苗采取严格监管措施，引发市场关注。分析人士指出，他的离任可能有助于缓解监管压力，被视为基因 疗法和疫苗企业的利好消息。 ...

Core Viewpoint - A lawsuit has been filed against Replimune Group, Inc. and its senior executives for potential violations of federal securities laws, following a significant decline in stock price after the FDA's response to their biologics license application for RP1 [1][2][5]. Group 1: Company Overview - Replimune is a clinical-stage biotechnology company focused on developing oncolytic immunotherapies for cancer treatment, with its lead product candidate being RP1 for melanoma [3]. - The company announced positive results from its IGNYTE Phase 1/2 clinical trial for RP1 in combination with nivolumab on June 6, 2024, and subsequently submitted a biologics license application to the FDA based on these results [3]. Group 2: Legal Issues - The lawsuit claims violations under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, representing investors who purchased Replimune securities [2]. - The complaint alleges that the IGNYTE Phase 1/2 trial design was inadequate to produce reliable results, despite the company promoting its outcomes [4]. Group 3: Stock Performance - Following the FDA's Complete Response Letter on July 22, 2025, which indicated that the IGNYTE trial was not considered adequate for demonstrating effectiveness, Replimune's stock price fell by more than 75% [5].